Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are gut hormones called incretins. They physiologically regulate metabolism and body weight via their receptors (GLP-1R and GIPR). GLP-1R agonists are effective in improving diabetes and obesity in clinical settings. Recent advances in the combination of GIPR agonism with GLP-1R agonism have shown superior efficacy to GLP-1R agonism only.

SCO-094, identified by SCOHIA researches and collaborators, is a novel dual agonist for GLP-1R and GIPR. Preclinical studies have shown that SCO-094 is more effective in improving diabetes and obesity than GLP-1R agonism only. In addition, SCO-094 has been shown to improve liver parameters in diabetic and obesity conditions in preclinical research. SCO-094 may be superior to the GLP-1R agonist in improving diabetes, obesity, and non-alcoholic steatohepatitis (NASH).

A long-acting formulation as well as an oral formulation of SCO-094, which is likely to maximize its therapeutic efficacy, are under development. A phase 1 study (first-in-human study), starting in 2020 is being organized in the UK.

Indication

  • Obesity
  • Diabetes
  • Activation
  • Benefits
SCO-094
GLP-1R
GIPR

Pancreas

Pancreas

Insulin secretion
Glucagon secretion

Brain

Brain

Food
intake

Stomach

Stomach

Gastric
emptying

Skeletal muscle

Skeletal muscle

Glucose
consumption

Liver

Liver

Glucose
production

GIPR

Pancreas

Pancreas

Insulin
secretion

Fat

Fat

Glucose
consumption

Blood glucose level

Body weight

GLP-1R : Glucagon-like peptide 1 receptor

GIPR : Glucose-dependent insulinotropic peptide receptor